Company Description
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.
It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.
In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome.
The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.
Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Dr. Adi Zuloff-Shani Ph.D. |
Contact Details
Address: 101-1220 West 6th Avenue Vancouver, British Columbia, Z4 V6H1A5 Canada (Federal Level) | |
| Phone | 972-54-5704749 |
| Website | clearmindmedicine.com |
Stock Details
| Ticker Symbol | CMND |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001892500 |
| ISIN Number | CA1850534027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Executive Officer |
| Prof. Mark Haden | Vice President of Business Development |
| Gilad Babchuk | Head of Strategy and Communication |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Mar 27, 2024 | 20-F/A | Filing |
| Mar 27, 2024 | 6-K | Report of foreign issuer |
| Mar 22, 2024 | EFFECT | Notice of Effectiveness |
| Mar 20, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Mar 18, 2024 | 20-F/A | Filing |
| Mar 13, 2024 | 6-K | Report of foreign issuer |
| Feb 27, 2024 | 6-K | Report of foreign issuer |